Autolus Therapeutics plc is continuing its work to become a pioneering cell therapy company in the space of AD. Learn more ...

Bank of Japan Deputy Governor Shinichi Uchida is currently in hospital to treat leukemia and will work remotely for a few ...

This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

A community in England is in mourning after a teenage boy, 16-year-old Harley Andrews, died just one day after being ...

The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.

4A10, a monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα; CD127), has received fast track designation from the FDA for the treatment of patients with relapsed or refractory acute ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

Like many college soccer players, University of Montevallo defender Will Mashburn is relentless in his work ethic on and off ...

Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1 -mutated AML who have no satisfactory ...

Two phase 3 trials will study Kura Oncology’s ziftomenib for frontline acute myeloid leukemia, one with venetoclax and the ...

Ziftomenib (Komzifti; Kura Oncology and Kyowa Kirin), an oral, once-daily, selective menin inhibitor, has received approval from the FDA for the treatment of adult patients with relapsed or refractory ...

The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia.